| 1 |
35444553 | Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva). | 2022 |
1 |
| 2 |
31588998 | PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. | 2019 Oct 7 |
1 |
| 3 |
28324268 | A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. | 2017 Jun |
1 |
| 4 |
28595616 | Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. | 2017 Jun 8 |
1 |
| 5 |
26983881 | An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. | 2016 Jun |
1 |
| 6 |
27185573 | Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. | 2016 Jul |
1 |
| 7 |
25239224 | Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer. | 2015 Feb |
2 |
| 8 |
26091915 | Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. | 2015 Oct |
2 |
| 9 |
26187616 | A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. | 2015 Dec 1 |
1 |
| 10 |
26199039 | Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. | 2015 Sep |
1 |
| 11 |
24827931 | Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation. | 2014 Nov |
1 |
| 12 |
24833916 | Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. | 2014 |
1 |
| 13 |
25173583 | Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. | 2014 Nov |
1 |
| 14 |
23211938 | Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. | 2013 Apr |
4 |
| 15 |
23403817 | Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. | 2013 Mar 19 |
1 |
| 16 |
23468082 | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. | 2013 May |
2 |
| 17 |
23492649 | Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. | 2013 |
1 |
| 18 |
23615181 | A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers. | 2013 Jun |
1 |
| 19 |
23659969 | A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. | 2013 Jul 1 |
7 |
| 20 |
23715582 | Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. | 2013 Jul 1 |
2 |
| 21 |
23829943 | A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. | 2013 Jul 8 |
2 |
| 22 |
23921574 | Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). | 2013 Oct |
2 |
| 23 |
23971829 | Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas. | 2013 Sep |
2 |
| 24 |
25431800 | Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. | 2013 |
1 |
| 25 |
30349605 | Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. | 2013 Mar |
1 |
| 26 |
21843915 | A role for maintenance therapy in managing sarcoma. | 2012 Aug |
2 |
| 27 |
22043997 | Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. | 2012 Feb |
1 |
| 28 |
22067397 | Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. | 2012 Jan 1 |
1 |
| 29 |
22143378 | Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. | 2012 Apr |
1 |
| 30 |
22231376 | Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. | 2012 May |
3 |
| 31 |
22290273 | The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. | 2012 May |
1 |
| 32 |
22614157 | Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. | 2012 Aug |
3 |
| 33 |
22669570 | The minimal impact of food on the pharmacokinetics of ridaforolimus. | 2012 Jul |
2 |
| 34 |
22695254 | Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. | 2012 Dec |
2 |
| 35 |
22815528 | Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. | 2012 Sep 1 |
1 |
| 36 |
22878520 | A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. | 2012 Oct |
1 |
| 37 |
22942649 | Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. | 2012 |
1 |
| 38 |
23098121 | Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. | 2012 Sep |
1 |
| 39 |
21482695 | Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. | 2011 Jun |
4 |
| 40 |
21825008 | Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. | 2011 Oct |
1 |
| 41 |
20855840 | Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. | 2010 Oct 20 |
1 |
| 42 |
20945947 | Ridaforolimus. | 2010 |
1 |
| 43 |
19228743 | A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. | 2009 Feb 15 |
3 |
| 44 |
18202410 | Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. | 2008 Jan 20 |
1 |
| 45 |
18451242 | A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. | 2008 May 1 |
1 |
| 46 |
19012509 | Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. | 2008 Dec |
1 |
| 47 |
16721131 | Mammalian target of rapamycin inhibitors in sarcomas. | 2006 Jul |
1 |
| 48 |
16952072 | Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer. | 2006 Sep |
3 |
| 49 |
16989597 | Investigating mammalian target of rapamycin inhibitors for their anticancer properties. | 2006 Oct |
1 |
| 50 |
17026798 | Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma. | 2006 Sep |
1 |